SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Boehringer Ingelheim Registers Phase III COPD Trial for Verducatib

Boehringer Ingelheim registered the AIRWARD Phase III trial investigating verducatib in COPD on ClinicalTrials.gov (NCT07907991).

Related stories